According to GlobalData’s medical device pipeline database, 20 Cellular Skin Substitutes devices are in various stages of development globally. GlobalData’s report Cellular Skin Substitutes provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, five are in active development, while the remaining 15 are in an inactive stage of development. There are one products in the early stages of development, and the remaining four are in the late stages of development.
Cellular Skin Substitutes contain viable cells seeded onto the matrix material. They provide serve as a barrier from the environment and reduce inflammation and scarring by supporting wound closure without excessive fibrosis. One unit of cellular skin substitutes refers to 9 sq. inch (58 sq.cm). This segment consists of cellular skin substitutes based on amniotic membrane and other cellular skin substitutes
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Cellular Skin Substitutes pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Cellular Skin Substitutes devices. Overall, most of these Cellular Skin Substitutes pipeline devices are being developed by private entities.
Key players involved in the active development of Cellular Skin Substitutes include Stratatech, MiMedx Group, Organogenesis, Lattice Biologics, Merakris Therapeutics and Amnio Technology.
For a complete picture of the developmental pipeline for Cellular Skin Substitutes devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
